ImmunoGen

$7.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+0.56%) As of 2:08 PM UTC today

Why Robinhood?

You can buy or sell ImmunoGen and other stocks, options, and ETFs commission-free!

About IMGN

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151.

CEO

Mark J. Enyedy

Employees

Headquarters

Waltham, Massachusetts

Founded

1981

Market Cap

1.49B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

2.04M

High Today

$7.30

Low Today

$7.15

Open Price

$7.15

Volume

208.88K

52 Week High

$10.88

52 Week Low

$3.34

Analyst Ratings

67%

of 9 ratings

Buy

67%

Hold

33%

Sell

IMGN Earnings

-$0.18

-$0.07

$0.05

$0.16

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected Apr 30, Pre-Market